Bioscience

Pfizer And Medivation start two Phase III studies of dimebon in Alzheimer’s disease patients

November 4, 2009

By Flinn Foundation

[Source: Therapeutics Daily] – US-based pharmaceutical company Pfizer Inc and Medivation Inc, a biopharmaceutical company, said yesterday they have initiated two Phase III studies of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer’s disease (AD).

Latrepirdine is the proposed generic (nonproprietary) name for dimebon. The two companies have a global collaboration to develop and commercialise dimebon for the treatment of Alzheimer’s disease and Huntington disease.

Pierre Tariot, director of the Memory Disorders Center at the Banner Alzheimer’s Institute and study investigator, said that the studies are intended to evaluate the potential added benefits of dimebon in combination with current standards of Alzheimer’s care.

For more information: Pfizer And Medivation start two Phase III studies of dimebon in Alzheimer’s disease patients